Nordea flags 56% upside in specialty pharma on low expectations

Nordea analysts argue that pessimistic investor sentiment has depressed expectations for a specialty pharmaceutical company, creating asymmetric upside if results beat low forecasts. The 56% upside estimate is a single-broker view, not corroborated, and hinges on earnings delivery. This matters as a stock-specific catalyst, not a macro signal.